PT  - JOURNAL ARTICLE
AU  - YASUHIRO KODERA
AU  - SEIJI ITO
AU  - YOSHINARI MOCHIZUKI
AU  - SHINICHI FUJITAKE
AU  - KATSUMI KOSHIKAWA
AU  - YASUAKI KANYAMA
AU  - TAKANORI MATSUI
AU  - HIROSHI KOJIMA
AU  - TSUNENOBU TAKASE
AU  - NORIFUMI OHASHI
AU  - MICHITAKA FUJIWARA
AU  - JUNICHI SAKAMOTO
AU  - AKIMASA NAKAO
AU  - for Chubu Clinical Cancer Group
TI  - A Phase II Study of Weekly Paclitaxel as Second-line Chemotherapy for Advanced Gastric Cancer (CCOG0302 Study)
DP  - 2007 Jul 01
TA  - Anticancer Research
PG  - 2667--2671
VI  - 27
IP  - 4C
4099  - http://ar.iiarjournals.org/content/27/4C/2667.short
4100  - http://ar.iiarjournals.org/content/27/4C/2667.full
SO  - Anticancer Res2007 Jul 01; 27
AB  - Background: Although paclitaxel was given triweekly in phase II trials prior to its approval for gastric cancer in Japan, it is currently more often delivered by a weekly schedule in the second-line setting. Patients and Methods: A phase II trial with response rate as the primary end-point was conducted. Patients with metastatic or unresectable gastric adenocarcinoma who had measurable lesions and had disease progression with the front-line chemotherapy were treated by weekly administration of paclitaxel at a dose of 80 mg/m2. Results: Forty-five patients were accrued and 44 were assessable for response. Partial responses were observed in 7 patients (16%). Stable disease was documented in further 14 patients (48%). Median progression-free survival of all patients enrolled was 2.6 months and median overall survival was 7.8 months. Toxicity was mild and manageable, the most frequent ≥grade 3 toxicity being neutropenia occurring in 16% of the patients. Conclusion: With modest response rate, favorable toxicity profile, and progression-free or overall survival similar to those of more intense combination regimens, weekly paclitaxel remains a rational therapeutic option for gastric cancer refractory to the first-line chemotherapy.